hernberg (27 resultados)

Condición: As New. Unread book in perfect condition.

Condición: New.

Paperback. Condición: New.

Condición: New.

Condición: As New. Unread book in perfect condition.

Condición: very good. Gut/Very good: Buch bzw. Schutzumschlag mit wenigen Gebrauchsspuren an Einband, Schutzumschlag oder Seiten. / Describes a book or dust jacket that does show some signs of wear on either the binding, dust jacket or pages.

Nuevo. Condición: En venta.

RUSTICA. Condición: Nuevo. Estado de la sobrecubierta: Nuevo. DISTRF.

Hardcover. Condición: Good. No Jacket. Author inscribed/signed on the front endpaper: "To Dr. D- Thank you for your great input and help in finishing this project! Sara." Tall hardcover. No DJ. master of Science thesis. Pages printed on one side. Content pages are clean and unmarked. 71 pages.

Proceedings of the Third Scientific Syimposium, Tallinn, October 19-20, 1983. Brown cloth-covered boards, 9 3/4 x 7 inches, 145 pp., figures, tables. In English and Russian, side-by-side. Near fine. Rare. (3214034).

Maier, Gundeslheim, (um 1960). 23 S., kart.--- 20 Gramm.

Paperback. Condición: New.

hardcover. Condición: Good. Good. Dust Jacket NOT present. CD WILL BE MISSING. . SHIPS FROM MULTIPLE LOCATIONS. book.

Condición: NUEVO. 348 pages/páginas.

Condición: new. New!

Hardcover. Condición: New.

Condición: New. pp. 334.

Hardcover. Condición: Brand New. 1st edition. 317 pages. 9.25x6.50x1.00 inches. In Stock.

Condición: New. pp. 334.

Condición: New. pp. 334.

Tagen ur band, titelsidan med ett påar små mörka fläckar och påskrift av en ordningssiffra i bläck. Upsala, tryckt hos Johan Edman, [1772]. 4:o. 58 s.

Condición: Very Good. Uppsala, hos Johan Edman, (1772). 4:o. (2),+ 58 s. Bitvis aningen lagerfläckig. Nära skuren, med minimal tryckförlust vid pagineringen s. 7 och 8, mindre pappersförlust i nedre marginalen till första och sista bladen. Grönt senare hkbd med svart ryggtiteletikett, marmorerade pärmpapper och sprängda snitt (Wilh. Johanssons eftr.). Kurt Winbergs exlibris på främre pärmens insida. Lidén I, s. 242. Hardcover / Hardback.

Leatherbound. Condición: NEW. BOOKS ARE EXEMPT FROM IMPORT DUTIES AND TARIFFS; NO EXTRA CHARGES APPLY. Leatherbound edition. Condition: New. Leather Binding on Spine and Corners with Golden leaf printing on spine. Bound in genuine leather with Satin ribbon page markers and Spine with raised gilt bands. Pages: 234. A perfect gift for your loved ones. Reprinted from 1915 edition. NO changes have been made to the original text. This is NOT a retyped or an ocr'd reprint. Illustrations, Index, if any, are included in black and white. Each page is checked manually before printing. As this print on demand book is reprinted from a very old book, there could be some missing or flawed pages, but we always try to make the book as complete as possible. Fold-outs, if any, are not part of the book. If the original book was published in multiple volumes then this reprint is of only one volume, not the whole set. IF YOU WISH TO ORDER PARTICULAR VOLUME OR ALL THE VOLUMES YOU CAN CONTACT US. Resized as per current standards. Sewing binding for longer life, where the book block is actually sewn (smythe sewn/section sewn) with thread before binding which results in a more durable type of binding. Language: Swedish Pages: 234.

Leather Bound. Condición: New. Language: Swedish. Language: Swedish. Presenting an Exquisite Leather-Bound Edition, expertly crafted with Original Natural Leather that gracefully adorns the spine and corners. The allure continues with Golden Leaf Printing that adds a touch of elegance, while Hand Embossing on the rounded spine lends an artistic flair. This masterpiece has been meticulously reprinted in 2024, utilizing the invaluable guidance of the original edition published many years ago in 1915. The contents of this book are presented in classic black and white. Its durability is ensured through a meticulous sewing binding technique, enhancing its longevity. Imprinted on top-tier quality paper. A team of professionals has expertly processed each page, delicately preserving its content without alteration. Due to the vintage nature of these books, every page has been manually restored for legibility. However, in certain instances, occasional blurriness, missing segments, or faint black spots might persist. We sincerely hope for your understanding of the challenges we faced with these books. Recognizing their significance for readers seeking insight into our historical treasure, we've diligently restored and reissued them. Our intention is to offer this valuable resource once again. We eagerly await your feedback, hoping that you'll find it appealing and will generously share your thoughts and recommendations. Lang: - Swedish, Pages: - 234, Print on Demand. If it is a multi-volume set, then it is only a single volume. We are specialised in Customisation of books, if you wish to opt different color leather binding, you may contact us. This service is chargeable. Product Disclaimer: Kindly be informed that, owing to the inherent nature of leather as a natural material, minor discolorations or textural variations may be perceptible. Explore the FOLIO EDITION (12x19 Inches): Available Upon Request. 234 234.

Condición: new. Questo è un articolo print on demand.

Buch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This authoritative and comprehensive book makes the reader familiar with the processes of bringing orphan drugs to the global market. There are between 5,000 and 7,000 rare diseases and the number of patients suffering from them is estimated to be more than 50 million in the US and Europe. Before the orphan drug legislation enacted in the US in 1983, there was a limited interest from industry to develop treatment for very small patient groups. One of the difficulties is, of course, that similar levels of investment are needed from a pharmaceutical company to bring a drug to the market for both small and large patient groups.The journey from application of an orphan drug designation to a reimbursed market- approved drug is long and many obstacles occur during the journey.After reading the book, readers will: Understand who the players/stakeholders are in the rare orphan disease field and their specific needs and concerns: patients and patient organizations, researchers and treating physicians within the field, industry, regulatory and reimbursement bodies\* Understand the strong partnership between the different players and the various initiatives to improve and increase access to treatment for patients; minimizing the gap between numbers of known diseases, orphan designations, approved drugs and paid drugs.The book also provides short practical case stories from patients and researchers, as well as representatives from industry and authorities on the challenges they came across in developing orphan drugs or getting access to orphan drugs. Englisch.

Buch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - This authoritative and comprehensive book makes the reader familiar with the processes of bringing orphan drugs to the global market. There are between 5,000 and 7,000 rare diseases and the number of patients suffering from them is estimated to be more than 50 million in the US and Europe. Before the orphan drug legislation enacted in the US in 1983, there was a limited interest from industry to develop treatment for very small patient groups. One of the difficulties is, of course, that similar levels of investment are needed from a pharmaceutical company to bring a drug to the market for both small and large patient groups.The journey from application of an orphan drug designation to a reimbursed market- approved drug is long and many obstacles occur during the journey.After reading the book, readers will: Understand who the players/stakeholders are in the rare orphan disease field and their specific needs and concerns: patients and patient organizations, researchers and treating physicians within the field, industry, regulatory and reimbursement bodies\* Understand the strong partnership between the different players and the various initiatives to improve and increase access to treatment for patients; minimizing the gap between numbers of known diseases, orphan designations, approved drugs and paid drugs.The book also provides short practical case stories from patients and researchers, as well as representatives from industry and authorities on the challenges they came across in developing orphan drugs or getting access to orphan drugs.